Trial Profile
COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Golimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms CONSUL
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 04 Jun 2022 Primary endpoint has not been met (Absolute progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) over two years of therapy (weeks 12-108) in the Phase II (core phase) of the trial) , according to Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism